SG11201804117XA - Neural cell extracellular vessicles - Google Patents

Neural cell extracellular vessicles

Info

Publication number
SG11201804117XA
SG11201804117XA SG11201804117XA SG11201804117XA SG11201804117XA SG 11201804117X A SG11201804117X A SG 11201804117XA SG 11201804117X A SG11201804117X A SG 11201804117XA SG 11201804117X A SG11201804117X A SG 11201804117XA SG 11201804117X A SG11201804117X A SG 11201804117XA
Authority
SG
Singapore
Prior art keywords
international
road
stice
athens
pct
Prior art date
Application number
SG11201804117XA
Inventor
Steven Stice
Robin Webb
Tracy Stice
Original Assignee
Univ Georgia
Aruna Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia, Aruna Biomedical Inc filed Critical Univ Georgia
Publication of SG11201804117XA publication Critical patent/SG11201804117XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau (43) International Publication Date ..... .....r .,„01 26 May 2017(26.05.2017) WIPO I PCT ID Hit (10) WO International 2017/087500 111111111111111111IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIMIIIIIIIIIIIIIII Publication Number Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 35/30 (2015.01) A61P 25/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 35/545 (2015.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2016/062245 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 16 November 2016 (16.11.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/256,823 18 November 2015 (18.11.2015) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: UNIVERSITY OF GEORGIA RESEARCH GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, FOUNDATION, INC. [US/US]; Boyd Graduate Studies TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Research Center, D.W. Books Drive, Athens, GA 30602- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 7411 (US). ARUNA BIOMEDICAL, INC.; 425 River DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Road, Georgia Bissiness Center, Athens, GA 30602 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: STICE, Sreven, L.; 380 River Road, Ahtens, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GA 30606-6433 (US). WEBB, Robin, Lynn; 1186 Robert GW, KM, ML, MR, NE, SN, TD, TG). Harderman Rd., Winterville, GA 30683 (US). STICE, Published: Tracy, A.; Traycy A. 380 River Road Bottom Road, Stice, 21(3)) with international search report (Art Athens, GA 30606 (US). (74) Agent: COLEMAN, Henry, D.; Cossud Intellectual Prop- erty Solution, P.C., 714 Colorado Avenue, Bridgeport, CT 06605-1601 (US). Il .4t C::: , C::: , In IN Ge C::: , IN l'I C::: , N (54) Title: NEURAL CELL EXTRACELLULAR VESSICLES C2 (57) : Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative diseases.
SG11201804117XA 2015-11-18 2016-11-16 Neural cell extracellular vessicles SG11201804117XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562256823P 2015-11-18 2015-11-18
PCT/US2016/062245 WO2017087500A1 (en) 2015-11-18 2016-11-16 Neural cell extracellular vessicles

Publications (1)

Publication Number Publication Date
SG11201804117XA true SG11201804117XA (en) 2018-06-28

Family

ID=58717775

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804117XA SG11201804117XA (en) 2015-11-18 2016-11-16 Neural cell extracellular vessicles

Country Status (15)

Country Link
US (3) US11993787B2 (en)
EP (1) EP3377078A4 (en)
JP (2) JP7075594B2 (en)
KR (1) KR20180086440A (en)
CN (1) CN108697740A (en)
AU (1) AU2016357303B2 (en)
BR (1) BR112018009891A2 (en)
CA (1) CA3004450A1 (en)
EA (1) EA201891152A1 (en)
HK (1) HK1256911A1 (en)
IL (1) IL259470B (en)
MX (1) MX2018005313A (en)
NZ (1) NZ742327A (en)
SG (1) SG11201804117XA (en)
WO (1) WO2017087500A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005313A (en) 2015-11-18 2018-09-05 Univ Georgia Neural cell extracellular vessicles.
US11073511B2 (en) * 2016-02-01 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Exosome-Total-Isolation-Chip (ExoTIC) device for isolation of exosome-based biomarkers
US20190383832A1 (en) 2017-12-29 2019-12-19 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
CN110317788A (en) * 2019-04-26 2019-10-11 广州瑞臻再生医学科技有限公司 A kind of preparation method and application of NPC culture medium, excretion body
CN118147050A (en) * 2019-06-10 2024-06-07 布瑞克斯奥根株式会社 Composition comprising tetrandrine for promoting production of stem cell-derived exosomes and increasing dryness
EP4034081A1 (en) * 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Extracellular vesicle compositions
JP2023500359A (en) * 2019-11-04 2023-01-05 アルナ バイオ， インコーポレーテッド Extracellular vesicles and their use for delivery of antibodies
KR102630220B1 (en) * 2019-11-12 2024-01-29 브렉소젠 주식회사 Composition for Protecting or Treating Kidney disease comprising Exosomes derived from Precursor cell of iPSC-derived mesenchymal stem cell
WO2021184020A1 (en) * 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
WO2021198954A1 (en) * 2020-03-31 2021-10-07 Universidade Do Minho Exosome-enriched extracellualr vesicles isolation, method and uses thereof
CN113577108B (en) * 2021-08-31 2023-07-07 中国科学院苏州纳米技术与纳米仿生研究所 Multifunctional collagen scaffold, preparation method and application thereof
CN113887569B (en) * 2021-09-09 2022-10-25 同济大学 Accident frequent region distinguishing method based on region scale
KR20230047936A (en) * 2021-10-01 2023-04-10 주식회사 입셀 Composition comprising component derived from induced pluripotent stem cell culture medium and uses thereof
WO2023056606A1 (en) * 2021-10-08 2023-04-13 Hangzhou Jijing Pharmaceutical Technology Limited Valproate (vpa) compounds for use in treating spinocerebellar ataxia type 1 (sca1)
JP7371975B1 (en) 2022-09-27 2023-10-31 セルソース株式会社 Method for producing extracellular vesicles and composition containing extracellular vesicles

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4440921A (en) 1982-06-21 1984-04-03 Research Corporation Coupling of polyorganophosphazenes to carboxylic acid
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4880622A (en) 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
EP1812556A4 (en) * 2004-10-05 2011-02-02 Univ Georgia Neuronal progenitors from feeder-free human embryonic stem cell culture
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
WO2006087233A2 (en) * 2005-02-21 2006-08-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells
PT2419144T (en) 2009-04-17 2019-09-16 Univ Oxford Innovation Ltd Composition for delivery of genetic material
AU2011288262A1 (en) 2010-08-13 2013-04-04 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related microRNAs
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2791336B1 (en) 2011-12-13 2017-11-29 Henry Ford Health System Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
SG11201406336YA (en) 2012-04-03 2014-11-27 Reneuron Ltd Stem cell microparticles
EP2885414B1 (en) * 2012-08-15 2020-09-23 The University of Chicago Exosome-based therapeutics against neurodegenerative disorders
US10308959B2 (en) 2013-01-18 2019-06-04 Henry Ford Health System Methods, systems, and compositions relating to MiRNA-146a
US11274139B2 (en) 2013-04-12 2022-03-15 Evox Therapeutics Ltd Therapeutic delivery vesicles
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
WO2015038065A1 (en) 2013-09-11 2015-03-19 Nanyang Technological University Plasma microvesicle biomarkers for ischemic stroke
WO2015038075A1 (en) * 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method
EP3057662A4 (en) 2013-10-17 2017-03-29 Children's Hospital Los Angeles Antibody dependent exosome therapy
FR3014198B1 (en) 2013-12-03 2017-03-03 Biomerieux Sa METHOD FOR ISOLATING EXOSOMES
CN103740645A (en) 2013-12-06 2014-04-23 山西医科大学 Preparation of neural stem cell-derived Exosomes, and application of neural stem cell-derived Exosomes in nervous system diseases
KR101661847B1 (en) 2014-03-18 2016-09-30 사회복지법인 삼성생명공익재단 Composition for treating inflammatory disease of brain comprising stem cell-derived exosome
WO2015161184A1 (en) 2014-04-18 2015-10-22 University Of Massachusetts Exosomal loading using hydrophobically modified oligonucleotides
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
EP3226875B1 (en) 2014-12-03 2020-05-27 Capricor, Inc. Processes for producing stable exosome formulations
WO2016172598A1 (en) 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
JP2018529340A (en) 2015-10-01 2018-10-11 ユニバーシティ・オブ・オタワ Exosome packaging of nucleic acids
MX2018005313A (en) 2015-11-18 2018-09-05 Univ Georgia Neural cell extracellular vessicles.
CN109415694A (en) 2016-04-29 2019-03-01 三星电子株式会社 For generating the method for being originated from the extracellular vesica of stem cell
US20220175842A1 (en) 2016-11-02 2022-06-09 Darwin J. Prockop Exosomes and uses thereof in diseases of the brain

Also Published As

Publication number Publication date
CA3004450A1 (en) 2017-05-26
CN108697740A (en) 2018-10-23
NZ742327A (en) 2020-01-31
EA201891152A1 (en) 2018-12-28
JP2022009194A (en) 2022-01-14
EP3377078A4 (en) 2019-09-04
US20190352603A1 (en) 2019-11-21
IL259470B (en) 2022-08-01
EP3377078A1 (en) 2018-09-26
MX2018005313A (en) 2018-09-05
AU2016357303A1 (en) 2018-05-10
WO2017087500A1 (en) 2017-05-26
KR20180086440A (en) 2018-07-31
JP2018534370A (en) 2018-11-22
US11993787B2 (en) 2024-05-28
IL259470A (en) 2018-07-31
AU2016357303B2 (en) 2023-11-30
WO2017087500A8 (en) 2018-05-31
US11111475B2 (en) 2021-09-07
US20180327714A1 (en) 2018-11-15
US20220356444A1 (en) 2022-11-10
BR112018009891A2 (en) 2018-12-26
JP7075594B2 (en) 2022-05-26
HK1256911A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
SG11201804117XA (en) Neural cell extracellular vessicles
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201407340YA (en) Treatment of myelosuppression
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201903032SA (en) Methods and compositions related to nk cell and anti-pdl1 cancer therapies
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201804268RA (en) Conjugates of quaternized tubulysin compounds
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201808539WA (en) Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease